159 related articles for article (PubMed ID: 35508556)
1. Preoperative prognostic factors for obstructive colorectal cancer.
Etienne JH; Salucki B; Bereder JM; Massalou D; Bentellis I; Goetschy M; Baqué P
Int J Colorectal Dis; 2022 Jun; 37(6):1257-1272. PubMed ID: 35508556
[TBL] [Abstract][Full Text] [Related]
2. Synchronous liver metastases and peritoneal carcinomatosis from colorectal cancer: different strategies for curative treatment?
Pinto A; Hobeika C; Philis A; Kirzin S; Carrère N; Ghouti L
Langenbecks Arch Surg; 2019 Jun; 404(4):477-488. PubMed ID: 31025165
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: Who will benefit from complete cytoreductive surgery?
Delhorme JB; Dupont-Kazma L; Addeo P; Lefebvre F; Triki E; Romain B; Meyer N; Bachellier P; Rohr S; Brigand C
Int J Surg; 2016 Jan; 25():98-105. PubMed ID: 26607853
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
5. Prior Surgical Score: An Analysis of the Prognostic Significance of an Initial Nondefinitive Surgical Intervention in Patients With Peritoneal Carcinomatosis of a Colorectal Origin Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy.
Paul BK; Ihemelandu C; Sugarbaker PH
Dis Colon Rectum; 2018 Mar; 61(3):347-354. PubMed ID: 29420428
[TBL] [Abstract][Full Text] [Related]
6. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP).
Cascales-Campos PA; López-López V; Torres-Melero J; Arjona A; Muñoz-Casares FC; Barrios P; Morales R; Pereira F; Bretcha-Boix P; González-Bayón L; González-Moreno S; Gil J
Clin Transl Oncol; 2020 Jan; 22(1):130-136. PubMed ID: 31049819
[TBL] [Abstract][Full Text] [Related]
8. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin.
Thomassen I; van Gestel YR; Lemmens VE; de Hingh IH
Dis Colon Rectum; 2013 Dec; 56(12):1373-80. PubMed ID: 24201391
[TBL] [Abstract][Full Text] [Related]
9. [The status analysis of diagnosis and treatment of synchronous peritoneal carcinomatosis from colorectal cancer in China: a report of 1 003 cases in 16 domestic medical centers].
Wang HM; Wang GY; Huang Y; Ren L; Zhang H; Wu AW; Han JG; Shu XG; Wang GY; Yang YC; Wang ZQ; Cui M; Lu Y; Feng B; Zhou JP; Wu B; Tong WD; Wang H; Luo YX; Wu XJ; Cai J; Yao HW; Wang L
Zhonghua Wai Ke Za Zhi; 2019 Sep; 57(9):666-672. PubMed ID: 31474058
[No Abstract] [Full Text] [Related]
10. Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Bong TSH; Tan GHC; Chia C; Soo KC; Teo MCC
Int J Clin Oncol; 2017 Jun; 22(3):511-518. PubMed ID: 28138878
[TBL] [Abstract][Full Text] [Related]
11. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer.
Lorimier G; Linot B; Paillocher N; Dupoiron D; Verrièle V; Wernert R; Hamy A; Capitain O
Eur J Surg Oncol; 2017 Jan; 43(1):150-158. PubMed ID: 27839895
[TBL] [Abstract][Full Text] [Related]
12. Analysis of patient selection policy and pattern of recurrence after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal carcinomatosis.
Robella M; Vaira M; Borsano A; DE Simone M
Minerva Chir; 2018 Apr; 73(2):133-141. PubMed ID: 29397633
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis.
Trilling B; Cotte E; Vaudoyer D; Isaac S; Piaton E; Maurice C; Glehen O; Passot G
Dis Colon Rectum; 2016 Jul; 59(7):615-22. PubMed ID: 27270513
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery and hyperthermic intraperitenoal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis.
Pallas N; Karamveri C; Kyziridis D; Hristakis C; Kyriakopoulos V; Kalakonas A; Vaikos D; Tentes AK
J BUON; 2017; 22(6):1547-1553. PubMed ID: 29332351
[TBL] [Abstract][Full Text] [Related]
15. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience.
Alzahrani NA; Valle SJ; Fisher OM; Sugarbaker PH; Yonemura Y; Glehen O; Goere D; Honore C; Brigand C; de Hingh I; Verwaal VJ; Deraco M; Baratti D; Kusamura S; Pocard M; Piso P; Maerz L; Marchal F; Moran B; Levine EA; Dumont F; Pezet D; Abboud K; Kozman MA; Liauw W; Morris DL;
J Surg Oncol; 2019 Mar; 119(3):336-346. PubMed ID: 30554404
[TBL] [Abstract][Full Text] [Related]
16. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
[TBL] [Abstract][Full Text] [Related]
17. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin.
Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745
[TBL] [Abstract][Full Text] [Related]
18. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Parikh R; Valle SJ; Arrowaili A; Alzahrani N; Liauw W; Morris DL
J Surg Oncol; 2018 Mar; 117(4):725-736. PubMed ID: 29266235
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer: The prognostic impact of baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios.
Zager Y; Hoffman A; Dreznik Y; Jacoby H; Cordoba M; Horesh N; Nevler A; Gutman M; Berger Y
Surg Oncol; 2020 Dec; 35():321-327. PubMed ID: 32977104
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
